Decheng Capital | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Decheng Capital/Activity

Decheng Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Led a ~$100M oversubscribed private placement in Remix Therapeutics ahead of its reverse merger with Passage Bio and Nasdaq listing as RMTX.

Remix Therapeutics

Remix Therapeutics Decheng Capital

globenewswire.comJUN 24, 2026

JUN 24, 2026

New Fund

Targeting $700M for its fifth flagship life sciences fund, larger than the $650M target for its 2020-vintage predecessor.

Decheng Capital Global Life Sciences Fund V

Decheng Capital

dealstreetasia.comOCT 6, 2025

OCT 6, 2025

Investment

Aardvark Therapeutics announced an oversubscribed $85M Series C financing.

Aardvark Therapeutics

Aardvark Therapeutics Decheng Capital

decheng.comMAY 9, 2024

MAY 9, 2024

Milestone

Mammoth Biosciences signed a gene-editing collaboration with Regeneron worth $100M upfront.

Mammoth Biosciences

Mammoth Biosciences Decheng Capital

decheng.comAPR 25, 2024

APR 25, 2024

Milestone

Cellares signed a $380M CAR-T cell therapy manufacturing supply deal with Bristol Myers Squibb.

Cellares

Cellares Decheng Capital

decheng.comAPR 22, 2024

APR 22, 2024

Exit

Portfolio company Alpine Immune Sciences agreed to be acquired by Vertex Pharmaceuticals for approximately $4.9 billion.

Alpine Immune Sciences

Alpine Immune Sciences Decheng Capital

decheng.comAPR 10, 2024

APR 10, 2024

Exit

Nuvation Bio agreed to acquire portfolio company AnHeart Therapeutics in an all-stock transaction.

AnHeart Therapeutics

AnHeart Therapeutics Decheng Capital

decheng.comMAR 25, 2024

MAR 25, 2024

Milestone

KeChow Pharma received NMPA approval for Tunlametinib, the first targeted therapy approved in China for NRAS-mutated advanced melanoma.

KeChow Pharma

KeChow Pharma Decheng Capital

decheng.comMAR 18, 2024

MAR 18, 2024

Investment

Nalu Medical closed an $85M Series E round.

Nalu Medical

Nalu Medical Decheng Capital

decheng.comMAR 5, 2024

MAR 5, 2024

Investment

Firefly Bio launched with a $94M Series A financing.

Firefly Bio

Firefly Bio Decheng Capital

decheng.comFEB 15, 2024

FEB 15, 2024

News

Portfolio company CG Oncology's shares surged 96% in its Nasdaq debut after an expanded IPO.

CG Oncology

CG Oncology Decheng Capital

decheng.comJAN 25, 2024

JAN 25, 2024

Exit

Merck completed its $10.8 billion acquisition of portfolio company Prometheus Biosciences.

Prometheus Biosciences

Prometheus Biosciences Decheng Capital

merck.comJUN 15, 2023

JUN 15, 2023